Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Wikimedia Creative Commons
Sarepta Therapeutics announced this morning it will sell its rare pediatric disease priority review voucher to Gilead Sciences for $125 million, giving Gilead the rights to have one of its drugs receive fast-track approval from the Food and Drug Administration.
The vouchers let drug companies get a decision on their medicines within six months, rather than the standard 10-plus months. The FDA awarded Sarepta the voucher last year at the same time the agency green-lighted Sarepta's drug that treats Duchenne muscular dystrophy, a move that was controversial at the time because there was disagreement over whether the drug was beneficial. Sarepta still has to conduct a clinical trial to back up the benefits of that drug.
Why this matters: Priority review vouchers have become valuable commodities as drug companies look for ways to jump ahead in the FDA line. There have been a handful of transactions in the decade that vouchers have been around. But Sarepta's $125 million deal fetched a lower price than the two most recent voucher sales of $350 million and $245 million. Analysts at investment bank Leerink Partners thought Sarepta could have gotten at least $200 million, raising questions of whether there is a "broader decline" of interest in the vouchers that command "increasingly astronomical" price tags.